Internal Medicine, Endocrinology, Diabetes, & Metabolism · Philadelphia, PA
NPI
1639203128
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
51 N 39th Street, Suite 2a
Philadelphia, PA, 19104
Phone (215) 662-9996
Groups this clinician bills Medicare through
Medicare paid, 2024
$33K
561 services
Medicare patients, 2024
207
Average age 72
Drug cost, 2024
$1.4M
2,932 prescriptions
Company payments, 2025
$113
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeremy J Flood was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 133 times for 93 patients. In total Jeremy J Flood billed 561 services in 14 codes, and Medicare paid $33K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-11-23.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 133 | 93 | $12.59 | $1,675 |
| 99214 Office E&M - Established | Facility | 100 | 81 | $75.85 | $7,585 |
| 99215 Office E&M - Established | Facility | 93 | 63 | $106.93 | $9,944 |
| 99232 Hospital E&M - Subsequent | Facility | 56 | 30 | $57.75 | $3,234 |
| 99222 Hospital E&M - Initial | Facility | 49 | 49 | $103.43 | $5,068 |
| 95251 Test - Miscellaneous | Facility | 49 | 33 | $27.34 | $1,340 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 47 | 41 | $13.02 | $612 |
By year: 2022 $32K for 430 services; 2023 $31K for 407 services; 2024 $33K for 561 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jeremy J Flood prescribed most often to Medicare patients was Atorvastatin Calcium, with 245 prescriptions and refills. In total Jeremy J Flood wrote 2,932 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 245 | 665 | 75 | $4,400 |
| Ozempic Semaglutide | 177 | 330 | 43 | $304K |
| Metformin Hcl Generic | 147 | 409 | 51 | $1,659 |
| Levothyroxine Sodium Generic | 142 | 358 | 42 | $1,530 |
| Mounjaro Tirzepatide | 132 | 253 | 44 | $262K |
| Jardiance Empagliflozin | 122 | 326 | 41 | $184K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 114 | 311 | 44 | $15K |
| Synthroid Levothyroxine Sodium | 103 | 307 | 30 | $12K |
| Metformin Hcl Er Metformin Hcl | 93 | 241 | 30 | $1,927 |
| Trulicity Dulaglutide | 85 | 146 | 25 | $142K |
| Novolog Flexpen Insulin Aspart | 74 | 141 | 28 | $17K |
| Rosuvastatin Calcium Generic | 72 | 198 | 27 | $1,358 |
| Methimazole Generic | 63 | 158 | 18 | $516 |
| Ezetimibe Generic | 61 | 154 | 18 | $2,158 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 56 | 146 | 27 | $8,447 |
Brand drugs: 1,350 claims; generic drugs: 1,376 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeremy J Flood $113 ($113 in general payments such as food, travel and fees) from 1 company. The largest payer was Novo Nordisk Inc with $113.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 1 | $113 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.